Withdrawn Drug Compound Library

Cat. No. : CS-L140 (195)
Library Contents: PDF | SDF

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 195 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Size (Pre-dissolved DMSO or Solid) Stock Price
30 μL/well (10 mM solution) In-stock Get quote
50 μL/well (10 mM solution) In-stock Get quote
100 μL/well (10 mM solution) In-stock Get quote
250 μL/well (10 mM solution) In-stock Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
* Country or Region:
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
* Phone number:
  Remarks:
 
Please slide the slider!
>>
 
Name, 
Organization name, 
Email address, 
Requested quantity, 
Phone number, 

Request SDF File

x

Please enter your email address. We will send your requested SDF file to you as soon as possible.

  • Data Sheet

  • Description & Advantages

  • Composition

  • Contents

Formulation:A collection of 195 withdrawn drug compounds supplied as pre-dissolved Solutions or Solid
Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:-80°C
Shipping:Blue ice

•    A unique collection of 195 Withdrawn Drug compounds for high throughput screening (HTS) and high content screening (HCS).

•    A useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

•   Target diverse, medicinally active and cell permeable.

•   More detailed compound information with structure, IC50, and other chemical & biological data.

•   High purity and quality validated by NMR and LC/MS.

PDF
Browsing History

    Customize Your Library

    You can select:
    • Specific Compounds
    • Quantities
    • Plate map
    • Concentration
    • Format (Solid or DMSO Solution)

    Please contact us at sales@chemscene.com

    Recommend Products
    CS-L138 Cat. No. : CS-L138

    (5729)

    Heterocyclic Compound Library

    CS-L144 Cat. No. : CS-L144

    (522 )

    Mitochondrial Protection Compound Library

    CS-L026 Cat. No. : CS-L026

    (1997 compounds)

    Clinical Compound Library